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OBJECTIVES: To estimate the medical and non-medical
resource use and related costs for the management of ﬁbromy-
algia patients in France from both the societal and the public
health care payer perspective. METHODS: A French expert
panel, involving 33 general practioners (GPs) and 27 rheuma-
tologists, was questioned in 2007 by means of a questionnaire
describing the UK prescriptions registered in the General Practice
Research Database between January 1998 and March 2003
(2260 ﬁbromyalgia patients). Participating experts were asked to
compare their own clinical practice to the UK prescriptions for
diagnostic tests, drugs, consultations and referrals, over a period
of four years before diagnosis to four plus years after diagnosis
using 1-year intervals. In addition, prescription data related to
paramedical and alternative care were collected. Costs were cal-
culated by multiplying prescribed resource use with correspond-
ing French unit costs (€; 2007; public health care payer
perspective (PHCPP) and societal perspective (SP) including
patient co-payments). Inpatient care and productivity loss were
not considered. RESULTS: The mean medical treatment cost
represents 345 euros per patient per year from the PHCPP (i.e.
84% visits, 9% drugs, 7% diagnostic tests) and €502 from the
SP. Including paramedical and alternative treatments, the esti-
mated cost is €414 per patient per year from a SP and €889 per
patient from a PHCPP. The costs of paramedical and alternative
treatments represent 16.7% and 43.5% of the total costs respec-
tively (of which 75% of paramedical acts, 20% alternative treat-
ment, 5% food supplements). The annual patient co-payment is
estimated at €475; €447 and €497 in resp. the rheumatologists
and the GP panel (i.e. 53, 51 and 55% of total costs).
CONCLUSIONS: In France, the cost of outpatient management
of ﬁbromyalgia is estimated at 889 euros per patient per year
from a SP and 414 from the PHCPP.
PMS35
RHEUMATOID ARTHRITIS COST STUDY RESULTS IN POLAND
Lacki J1, Rys P2, Plisko R2, Szamotulska K3, Szkultecka-Debek M4,
Russel-Szymczyk M4
1Institute of Rheumatology,Warsaw, Poland, 2HTA Consulting, Krakow,
Poland, 3National Research Institute of Mother and Child,Warsaw,
Poland, 4Roche Polska,Warsaw, Poland
OBJECTIVES: Analysis of Rheumatoid Arthritis (RA) treatment
patterns and associated health care resource use in patients
treated unsuccessfully with at least two DMARDs (including
metotrexate) in order to evaluate the costs of RA treatment.
METHODS: Multi-center, non-interventional, retrospective
study of 154 patients with rheumatoid arthritis diagnosed in
accordance with the revised criteria of the American Rheumatism
Association (1987). DAS 28 score  3.2 and prior inadequate
response to at least two DMARDs (including MTX). Data on RA
treatment patterns and associated health care resource use at
different levels of disease activity were collected between 2004
and 2007. Costs of hospitalizations, visits at outpatient clinics,
outpatient pharmacological treatment, therapeutic rehabilita-
tion, during the ﬁrst 6 months of the study for each patient were
taken into account. RESULTS: Median total cost in ﬁrst 6
months of observation period was 1203.45 PLN/patient/month
(€356). Hospitalization related cost was 661.52 PLN/patient/
month (€195,7), ambulatory treatment cost 415.70 PLN/patient/
month (123€). Total and hospital costs were signiﬁcantly
negatively correlated with patients’ age (Spearman’s
rho = -0.186 and -0.218, respectively). Higher DAS 28 score
signiﬁcantly increased total, hospital and ambulatory costs
(Spearman’s rho = 0.362, 0.210 and 0.190, respectively). There
was a tendency toward cost reduction with absence of concomi-
tant diseases, university degree of patient and earlier calendar
year of start of the treatment, especially after exclusion of
DMARDS. CONCLUSIONS: Rheumatoid arthritis cost studies
should take into account local factors inﬂuencing treatment pat-
terns (like patient’s age) in evaluation of costs of RA treatment.
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BACKGROUND: Anti-TNF therapies have proved to be efﬁca-
cious in clinical trials for the treatment of patients with rheuma-
toid arthritis (RA). However, it is unknown, how often patients
on anti-TNF therapy need dose escalation to try to recover lost
effectiveness and how effective this dose escalation is. The poten-
tial economic impact of this phenomenon is of interest to health
care budget-holders and decision-makers. OBJECTIVES: To
assess the cost of the therapy in Italy in patients with RA treated
with anti-TNF therapy (inﬂiximab, IFX), etanercept (ETN) and
adalimumab (ADA) for 36 months. METHODS: Patients attend-
ing participating centres who had received their ﬁrst anti-TNF
therapy between July 1, 2002 and March 31, 2004, and who
gave their consent, were invited to participate in the study.
Patients were required to be 18 years old, with a diagnosis of
RA (deﬁned by the ACR criteria). A total of 711 patients were
enrolled in this retrospective cohort study involving a national
representative sample of 23 rheumatology centres in Italy
selected according to both geography and treatment setting char-
acteristics. A patient chart review was conducted to collect data
on anti-TNF treatments, and a diary of therapies was completed.
Drugs acquisition costs were those ofﬁcially available on Decem-
ber 2007. RESULTS: Patients’ baseline characteristics were:
female 80.8%, mean age 53.3 years (range 18–84 years), mean
duration of disease 9.4 years. Of 703 patients who met the
inclusion criteria, 248 (35.3%) were treated with IFX, 259
(36.8%) with ETN and 196 (27.9%) with ADA. After a
follow-up of 36 months on the Kaplan—Meier curve, dose-
modiﬁcation was observed in 34.3%, 4.22% and 6.26% of
patients treated with IFX, ETN and ADA, respectively. The dose
modiﬁcation of IFX compared with ETN and ADA was statisti-
cally higher (p = 0.0001 for both). The difference between ADA
and ETN was not statistically signiﬁcant (p = 0.552). The
number of patients with a complete follow up of 36 months
were: 98 for IFX, 145 ETN and 112 ADA. Overall, costs of
treatment over 36 months of follow-up for these three cohorts of
patients were: IFX €28,186.60 (SD 10236,87); ETN €36.541,16
(SD 10,603.65); ADA €38,215.85 (SD11,558.27). This equals to
a 29.6% increase of costs of therapy for IFX, 4,4% for ADA.
ETN had a minor decrease of 2.1%. CONCLUSIONS: Our data
support that dose modiﬁcation is a common strategy in RA
patients treated with anti-TNFs biologics and its impact on treat-
ment costs is sensible and must be carefully evaluated by health
care budget-holders and decision-makers.
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